> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Safety-Related Labeling Changes Posted
- URL: https://www.fdaweb.com/safety-related-labeling-changes-posted/
- Published: 2020-11-17T12:00:00.000Z
- Updated: 2026-09-14T16:36:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148101

FDA has posted safety-related labeling [changes](https://webmail.emailsrvr.com/versions/webmail/18.1.9-RC/popup.php?wsid=17d9d7b4b011436197cbdd3fd18064e1-eedec2875e494533a7e5326b71b18c52&ref=fdaweb.com#1605632647967) for five biologics. The change for Merck’s Keytruda (pembrolizumab) involves the potential for infusion reactions added to the Warning and Precautions section of the labeling.

Changes were also posted for EMD Serono/Pfizer’s Bevencio (avelumab), Lilly’s Erbitux (cetuximab), AstraZeneca’s Imfinzi (durvalumab), and Regeneron’s Libtayo (cemiplimab-rwlc).